ArticleVirologica Sinica2025
Comparative analysis between genotypes of adenovirus isolates from hospitalized children with acute respiratory tract infections and clinical manifestations in Wuhan, China, from June 2022 to September 2023.
Article in Virologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes.Virologica Sinica · 2026Article
- Genomic characterization and evolutionary dynamics of human adenovirus C (HAdV-C) in Beijing (2023-2024): insights into multiple recombination and adaptive evolution.Virus evolution · 2026Article
- Genomic Characterization of Human Adenovirus Type 21 Strains - 7 PLADs, China, 2023-2024.China CDC weekly · 2025Article
- Genetic analysis of human adenovirus type 108 circulating in China during 2014-2024.Virologica Sinica · 2025Article
- [Analysis of Adenovirus Detection Trends in the Republic of Korea (2023-2024)].Jugan geon-gang gwa jilbyeong · 2025Article
- Proteomic characteristics of bronchoalveolar lavage fluid in children with mild and severeFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory tract infections (ARTIs) are among the leading causes of morbidity and mortality in children worldwide. Human adenovirus (HAdV) infections are estimated to account for at least 5% of pediatric ARTIs. The circulated genotypes of HAdV and the correlation between genotype and clinical manifestations in Wuhan, China, before and after the complete relaxation of nonpharmaceutical interventions against severe acute respiratory syndrome coronavirus 2, remain unknown. Here, 101 HAdV strains were isolated from throat swab samples collected from hospitalized children with ARTIs who tested positive for HAdV nucleic acid. Of these, sixty-six strains from 2022 to twenty-three strains from 2023 were successfully genotyped and subjected to phylogenetic analysis based on the hexon, penton base, and fiber genes. Six genotypes, B3, C1, C2, C5, C104, and C108 were identified. HAdV-B3 (84.85%) was the most prevalent type in 2022, while HAdV-C (86.96%), including C1, C2, C108, and C104, was the most prevalent in 2023. These strains were phylogenetically related to strains from Japan, China, and the United States in recent years. When comparing clinical characteristics, pediatric patients infected with B3, C1, C2, C5, C104, or C108 exhibited similar clinical manifestations, primarily fever and cough, but varying interleukin (IL)-10 levels. In conclusion, from June 2022 to September 2023, the circulated genotypes of HAdV in Wuhan included B3, C1, C2, C108, C5, and C104. The endemic pattern of HAdV in Wuhan, China, shifted from species B as the dominant type in 2022 to species C in 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.